睾酮替代治疗对迟发性性腺功能减退患者前列腺病变影响的Meta分析  

Effect of testosterone replacement therapy on prostate diseases in patients with late-onset hypogonadism:a Meta-analysis

作　　者：龚家郡 郭强[2] 张奥 任婧 郝川[2] GONG Jiajun;GUO Qiang;ZHANG Ao;REN Jing;HAO Chuan(The Second School of Clinical Medicine,Shanxi Medical University,Taiyuan 030000,Shanxi,China;Department of Urology,the Second Hospital of Shanxi Medical University,Taiyuan 030000,Shanxi,China;Department of Urology,Jining Third People′s Hospital,Jining 272000,Shandong,China)

机构地区：[1]山西医科大学第二临床医学院,太原030000 [2]山西医科大学第二医院泌尿外科,太原030000 [3]济宁市第三人民医院泌尿外科,山东济宁272000

出　　处：《中国性科学》2023年第2期1-4,共4页Chinese Journal of Human Sexuality

基　　金：山西省自然科学基金(201901D111365)。

摘　　要：目的评估睾酮替代治疗(TRT)对迟发性性腺功能减退(LOH)患者前列腺病变的影响。方法计算机检索中国知网(CNKI)、万方、PubMed、Embase、Cochrane library、Web of science等数据库,搜索建库至2021年6月发表的TRT对LOH患者前列腺相关疾病影响的随机对照试验(RCT)。由2名研究者按照纳入与排除标准确定最终纳入文献,获取纳入文献的资料并进行质量评价后,采用RevMan5.3软件进行Meta分析。结果共纳入10篇RCT,共1981例患者。Meta分析结果显示,无论干预时程≥12个月或<12个月,睾酮剂型为睾酮、十一酸睾酮或庚酸睾酮,给药方式为肌注、经皮或口服,剂量为≥100mg或<100mg,睾酮组与对照组前列腺癌、前列腺活检、前列腺结节比较,差异无统计学意义(P>0.05);干预时程<12个月、睾酮剂型为睾酮,以及给药方式为经皮,睾酮组与对照组前列腺特异性抗原水平的变化比较,差异具有统计学意义(P<0.001)。结论TRT会导致前列腺特异性抗原水平的升高,但无法证明会增加LOH患者前列腺病变的发生、发展风险。Objective To evaluate the effect of testosterone replacement therapy(TRT)on prostate diseases in patients with late-onset hypogonadism(LOH).Methods Randomized controlled trial(RCT)on the effect of TRT on prostate-related diseases in patients with LOH were searched by computer from CNKI,Wanfang,PubMed,Embase,Cochrane library,Web of science and other databases until June 2021.Two researchers determined the final included references according to inclusion and exclusion criteria.After obtaining the data of included references and conducting quality evaluation,Meta-analysis was performed using RevMan5.3 software.Results A total of 10 RCT with a total of 1,981 patients were included.Meta-analysis showed that no matter the intervention duration≥12 months or<12 months,testosterone dosage forms were testosterone,testosterone undecanoate or testosterone enanthate,and administration was intramuscular,percutaneous or oral,the dose was≥100mg or<100mg,testosterone group and control group compared with prostate cancer,prostate biopsy,prostate nodules,the difference was not statistically significant(P>0.05).There were statistically significant differences in prostate specific antigen levels between the testosterone group and the control group at intervention duration<12 months,testosterone dosage form was testosterone and percutaneous administration(P<0.001).Conclusions TRT is associated with increased prostate specific antigen levels,but has not been shown to increase the risk of prostate diseases occurrence and development in patients with LOH.

关 键 词：迟发性性腺功能减退 睾酮 前列腺病变 META分析 随机对照试验 

分 类 号：R697[医药卫生—泌尿科学]